0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Mucin-1

Mucin-1

Brief Information

Name:Mucin-1
Target Synonym:Polymorphic epithelial mucin,PUM,MUC1-NT,Episialin,CD227,MUC1-CT,MUC1,Mucin 1, Cell Surface Associated,Tumor-Associated Epithelial Membrane Antigen,Peanut-Reactive Urinary Mucin,Carcinoma-Associated Mucin,Krebs Von Den Lungen-6,CA 15-3,H23AG,MUC-1,KL-6,PE
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:16
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data

MU1-H82E5-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of Anti-Mucin-1 CAR-293 cells were stained with 100 μL of 0.1 μg/mL of Biotinylated Human Mucin-1, His,Avitag (Cat. No. MU1-H82E5) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (Routinely tested).

MU1-H52H5-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of anti-Mucin-1 CAR-293 were stained with 100 μL of 0.1 μg/mL of Human Mucin-1, His Tag (Cat. No. MU1-H52H5) and negative control protein respectively, washed and then followed by PE anti-His Tag antibody and analyzed with FACS (Routinely tested).

MU1-H52H9-ELISA
Human Mucin-1 (890-1158), His TagHuman Mucin-1 (890-1158), His Tag (Cat. No. MU1-H52H9) ELISA bioactivity

Immobilized Human Mucin-1 (890-1158), His Tag (Cat. No. MU1-H52H9) at 1 μg/mL (100 μL/well) can bind Anti-Mucin-1 Antibody, Mouse IgG1 with a linear range of 0.4-6 ng/mL (QC tested).

MU1-H5254-ELISA
Human Mucin-1 (24-380), Fc TagHuman Mucin-1 (24-380), Fc Tag (Cat. No. MU1-H5254) ELISA bioactivity

Immobilized Human Mucin-1 (24-380), Fc Tag (Cat. No. MU1-H5254) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Mucin-1 Antibody, Mouse IgG1 (SM-3) with a linear range of 0.5-4 ng/mL (QC tested).

Synonym Name

Mucin 1,MUC1,CD227,EMA,H23AG,KL-6,MAM6,MUC-1,SEC,MUC-1,X,MUC1,ZD,PEM,PEMT,PUM,CA15-3,Episialin

Background

Membrane mucins have several functions in epithelial cells including cytoprotection, extravasation during metastases, maintenance of luminal structure, and signal transduction. MUC17, contains an extended, repetitive extracellular glycosylation domain and a carboxyl terminus with two EGF-like domains, a SEA module domain, a transmembrane domain, and a cytoplasmic domain with potential serine and tyrosine phosphorylation sites. Interacts via its C-terminus with PDZK1 and this interaction appears important for proper localization. Probably plays a role in maintaining homeostasis on mucosal surfaces.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
ICTCAR043 ICTCAR043 Phase 1 Clinical Innovative Cellular Therapeutics Co Ltd Breast Neoplasms Details
Anti MUC 1 chimeric antigen receptor T cell therapy (Innovative Cellular) Phase 1 Clinical Innovative Cellular Therapeutics Co Ltd Pancreatic Neoplasms; Breast Neoplasms; Lung Neoplasms Details
Gatipotuzumab GT-MAB-2.5-GEX Phase 2 Clinical Nemod Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
huMNC2-CAR44 huMNC2-CAR44 Phase 1 Clinical Minerva Biotechnologies Breast Neoplasms Details
Anti-MUC1 CAR T cell (Guangzhou Anjie Biomedical) Phase 2 Clinical Guangzhou Anjie Biomedical Technology Esophageal Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Anti-MUC1 monoclonal antibody (OncoQuest) AR20.5; mAb-AR20.5; Anti-MUC1 AR20.5 Phase 2 Clinical Altarex Pancreatic Neoplasms Details
Anti-CD3/MUC1-armed cytokine induced killer cells Phase 2 Clinical Benhealth Biopharmaceutical (Shenzhen) Co Ltd Liver Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms Details
ICTCAR046 ICTCAR046 Clinical Innovative Cellular Therapeutics Co Ltd Pancreatic Neoplasms Details
MUC1-Poly-ICLC MUC1-poly-ICLC Phase 2 Clinical University Of Pittsburgh Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Recombinant HSP-MUC1 fusion protein (Newsummit) Phase 1 Clinical Shanghai Xinshengyuan Biological Medicine Co Ltd Breast Neoplasms Details
Anti-MUC1 CAR T-cell therapy (Guangzhou Anjie Biomedical Technology/University of Technology Sydney) Phase 2 Clinical The First Affiliated Hospital Of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology, University of Sydney Carcinoma, Non-Small-Cell Lung Details
GO-2032c GO-203-2C Phase 2 Clinical Genus Oncology Llc, Dana-Farber Cancer Institute Solid tumours; Leukemia, Myeloid, Acute Details
M-1231 M-1231 Phase 1 Clinical Emd Serono Research & Development Institute Inc Solid tumours; Esophageal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Adenoviral MUC1 vaccine (Etubics) Ad5-MUC1; ETBX-061 Phase 2 Clinical Etubics Corporation Liver Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Chordoma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung Details
CART-TnMUC1 Phase 1 Clinical University Of Minnesota, University Of Pennsylvania Ovarian Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Multiple Myeloma; Breast Neoplasms; Carcinoma, Pancreatic Ductal; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung Details
TG-4010 VV-MUC-IL2; TG-4010 Phase 2 Clinical Transgene Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) CVAC-301; CV-301 Phase 3 Clinical Therion Biologics Ovarian Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop